Trump's Tariff Threat, Retail Earnings Ahead of Black Friday, Amgen Tumbles on Weight-Loss Drug Data 11/26/24
Nov 26, 2024
auto_awesome
The discussion kicks off with President-elect Trump's tariff threats, stirring concerns in various market sectors. With Black Friday approaching, earnings from retailers like Best Buy are analyzed for holiday quarter insights. Amgen faces a stock slide due to disappointing results from its weight-loss drug trials. The hosts delve into Bitcoin's recent downturn and examine the innovative AI sounds being pioneered by Nvidia. Tensions heat up with a look at the geopolitical landscape affecting major oil players like Chevron and Exxon.
Trump's proposed tariffs on imports are causing market volatility and raising concerns about their long-term impacts on trade and inflation.
Amgen's disappointing obesity drug trial results underscore the challenges of competing in a market dominated by established players like Eli Lilly.
Deep dives
Market Reactions to Tariffs and Retail Earnings
The announcement of new import tariffs by the president-elect is generating mixed reactions in the stock market, with futures showing volatility. The tariffs include a 25% levy on products from Mexico and Canada and an additional 10% on goods from China. Retail earnings reports are also influencing market behavior, as some retailers signal strong performance entering the holiday season while others struggle. Analysts are keeping a close eye on how these economic changes may impact consumer spending and inflation in the coming months.
Challenges Facing Amgen's Weight Loss Drug
Amgen's experimental obesity drug, which showed weight loss results of up to 20%, is receiving disappointing reactions from investors due to results falling short of expectations. Analysts pointed out concerns related to gastrointestinal side effects that may hinder its acceptance in the market. The company stands at a crossroads, as it's essential for the drug to demonstrate significant advantages over existing treatments to gain traction. Despite its potential, analysts caution that it may not be enough to compete against well-established competitors like Eli Lilly and Novo Nordisk.
Tariffs and the Complexities of International Trade
The discussion around tariffs highlights the complexities of international trade and their potential impact on the domestic economy. Past experiences illustrate that while tariffs may serve as negotiating tools, they also risk retaliatory measures that could disrupt markets. Investors express concern over the unclear long-term implications of these trade policies on currencies and overall market dynamics. The situation is further complicated by the differing reactions among trading partners and their histories with the U.S., particularly in terms of steel imports and trade negotiations.
Emerging Investment Strategies Amid Market Shifts
In light of ongoing changes in the economic landscape, investors are increasingly turning to alternative investment strategies. As sectors like technology and consumer goods experience volatility, there is a noticeable shift towards companies positioned for growth, such as those involved in generative AI and electric vehicles. Discussions surrounding firms like NVIDIA are particularly relevant, as innovations in AI may play a crucial role in shaping future market dynamics and investment opportunities. Overall, the sentiment is that investors must remain agile, adapting to rapid changes while assessing potential risks and rewards.
Carl Quintanilla, Jim Cramer and David Faber explored President-elect Trump's threat to impose tariffs on Mexico and Canada and raise them on China. What’s at stake for certain sectors in this market? With Black Friday just days away, the anchors discussed earnings and holiday quarter guidance from the likes of Best Buy and Dick's Sporting Goods. Also in focus: Shares of Amgen tumble after a mid-stage trial for its experimental obesity drug misses analyst expectations, President Biden proposes requiring Medicare and Medicaid to cover weight-loss drugs, bitcoin extends post-record slide, California Gov. Newsom vs. Elon Musk, Nvidia's new AI sound model.